How are Conjugated Estrogens adverse event reports trending over time?
This graph shows volume of adverse events submitted to the FDA by quarter for Conjugated Estrogens, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Conjugated Estrogens is flagged as the suspect drug causing the adverse event.
What are the most common Conjugated Estrogens adverse events reported to the FDA?
Breast Cancer | 95 (14.57%) |
Breast Cancer Female | 75 (11.5%) |
Breast Cancer Metastatic | 25 (3.83%) |
Oestrogen Receptor Assay Positive | 11 (1.69%) |
Breast Cancer In Situ | 9 (1.38%) |
Condition Aggravated | 9 (1.38%) |
Dyspnoea | 9 (1.38%) |
Ovarian Cancer | 9 (1.38%) |
Progesterone Receptor Assay Positiv... | 9 (1.38%) |
Headache | 8 (1.23%) |
Major Depression | 8 (1.23%) |
Show More |
Share/Embed Graph Export Data
This graph shows the top adverse events submitted to the FDA for Conjugated Estrogens, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Conjugated Estrogens is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
What are the most common Conjugated Estrogens adverse events reported to the FDA?
Breast Neoplasms Malignant And Unsp... | 208 (31.9%) |
Reproductive Neoplasms Female Malig... | 26 (3.99%) |
Endocrine Investigations | 20 (3.07%) |
Embolism And Thrombosis | 18 (2.76%) |
Depressed Mood Disorders | 13 (1.99%) |
Neurological | 13 (1.99%) |
Therapeutic And Nontherapeutic Effe... | 13 (1.99%) |
Infections - Pathogen Unspecified | 12 (1.84%) |
Respiratory | 10 (1.53%) |
Suicidal And Self-injurious Behavio... | 10 (1.53%) |
Cardiac And Vascular Investigations | 9 (1.38%) |
Show More |
Share/Embed Graph Export Data
This graph shows the top categories of adverse events submitted to the FDA for Conjugated Estrogens, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Conjugated Estrogens is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
Why are people taking Conjugated Estrogens, according to those reporting adverse events to the FDA?
Hormone Replacement Therapy | 810 |
Drug Use For Unknown Indication | 43 |
Menopausal Symptoms | 31 |
Menopause | 24 |
Oestrogen Replacement Therapy | 14 |
Product Used For Unknown Indication | 11 |
Show More |
Label | Labeler | Effective |
---|---|---|
Cenestin | Physicians Total Care, Inc. | 01-SEP-04 |
Cenestin | Teva Women's Health Inc. | 01-SEP-04 |
Enjuvia | Duramed Pharmaceuticals Inc. | 01-MAR-10 |
Enjuvia | Physicians Total Care, Inc. | 01-MAR-10 |
Premarin | State of Florida DOH Central Pharmacy | 27-MAY-10 |
Premarin | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. | 30-NOV-10 |
Premarin | Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC | 21-MAR-12 |
Premarin | Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC | 22-MAR-12 |
Premarin Vaginal | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. | 10-MAY-12 |
Premarin | Cardinal Health | 22-JUN-12 |
Premarinvaginal | Physicians Total Care, Inc. | 22-JUN-12 |
Premarin | Aphena Pharma Solutions - Tennessee, Inc. | 18-JUL-12 |
Premarin | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. | 30-JUL-12 |
Premphase | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. | 30-SEP-12 |
Prempro | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. | 30-SEP-12 |
Prempro | Physicians Total Care, Inc. | 01-NOV-12 |
Premphase | Physicians Total Care, Inc. | 26-NOV-12 |
Prempro | Dispensing Solutions, Inc. | 27-FEB-13 |
Premarin | Cardinal Health | 17-APR-13 |
Premarin | Cardinal Health | 30-APR-13 |
What Conjugated Estrogens safety concerns are being reported by doctors and researchers in the medical literature?
This report contains aggregated drug side effects and adverse events for Conjugated Estrogens. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.
DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.
DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.
Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.
Share your experience with Conjugated Estrogens.